Freeline to Participate in Upcoming Investor Conferences in September 2021
Freeline Therapeutics (Nasdaq: FRLN), a clinical-stage biotechnology firm, announced its CEO, Michael Parini, will present at two upcoming virtual investor conferences. The H.C. Wainwright 23rd Annual Global Investment Conference is set for September 13, 2021, with a fireside chat available on-demand. The Morgan Stanley 19th Annual Global Healthcare Conference will take place on September 15, 2021, at 8:45 a.m. ET. Both webcasts will be accessible for 90 days on the company’s website. Freeline focuses on AAV-mediated gene therapies for inherited systemic diseases.
- None.
- None.
LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that Chief Executive Officer Michael Parini is scheduled to present at the following virtual investor conferences:
- H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, Fireside Chat that will be made available on-demand starting at 7:00 a.m. ET.
- Morgan Stanley 19th Annual Global Healthcare Conference on September 15, 2021, Fireside Chat at 8:45 a.m. ET.
Webcasts for both presentations will be available on the Investors section of the Freeline website for 90 days. Senior management will also participate in virtual one-on-one meetings with investors at both conferences.
About Freeline Therapeutics
Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (“AAV”) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases. Freeline uses its proprietary, rationally-designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing protein into the patient’s bloodstream. The Company’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing and commercialization. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease Type 1 and Hemophilia A. Freeline is headquartered in the UK and has operations in Germany and the US.
Contact
David S. Arrington
Vice President Investor Relations & Corporate Communications
Freeline Therapeutics
david.arrington@freeline.life
+1 (646) 668 6947
FAQ
What are the dates of Freeline Therapeutics' upcoming investor presentations?
Where can I watch Freeline Therapeutics' investor presentations?
Who is the CEO of Freeline Therapeutics?
What is the primary focus of Freeline Therapeutics?
Will Freeline's management have any investor meetings?
